20190513-Resultats-Q1-2019-EN-
Category: Press release
Transgene receives FDA IND Clearance for Lead myvac® Individualized Immunotherapy, TG4050, to Commence Clinical Development in Ovarian Cancer
20190513 PR IND TG4050 EN
Transgene Announces Upcoming Investor Meetings
20190509 PR financial meetings Q2 19
Availability of Preparatory Documents for the Combined General Meeting of May 22, 2019
20190509MISE A DISPO AG – US
Transgene and AstraZeneca enter into a collaboration and exclusive license option agreement for innovative Invir.IO(TM) based armed oncolytic immunotherapies
20190502 – TG-AZ agreement – ENG
Transgene and BioInvent Extend their Collaboration to Develop Multifunctional Oncolytic Viruses for the Treatment of Solid Tumors
20190326 PR BioInvent extension CDR US
Transgene: A positive 2018, moving ahead with a strong portfolio
20180320 FY RESULTS EN
Transgene secures a €20 Million Revolving Credit Facility with Natixis
20190318 PR Natixis loan EN
NEOVIVA project supporting the development of myvac® awarded a €5.2 million grant from Bpifrance’s “Investments for the Future” programme
20190313 – Neoviva – EN
Transgene to start clinical development of lead myvac® individualized immunotherapy, TG4050, in 2019, under its partnership with NEC
20190305-PR-NEC-Agreement-US-1